Win Where Requip Failed Enter Ticker Symbol or Company Name · CBS News / CBS Evening News / CBS...
Transcript of Win Where Requip Failed Enter Ticker Symbol or Company Name · CBS News / CBS Evening News / CBS...
CBS News / CBS Evening News / CBS This Morning / 48 Hours / 60 Minutes / Sunday Morning / Face The Nation / CBSN Log In
MarketsMarkets MoneyMoney WorkWork Small BusinessSmall Business RetirementRetirement TechTech TrendingTrending VideoVideo
By JIM EDWARDS / MONEYWATCH / September 17, 2008, 2:52 PM
GlaxoSmithKline Bets Solzira CanWin Where Requip Failed
Last Updated Sep 17, 2008 2:52 PM EDT
GlaxoSmithKline's announcement yesterday thatit is submitting a new drug application for Solzira tothe FDA for the treatment of Restless Legs Syndromeraises a question: What was wrong with its oldtreatment for RLS, Requip, launched only in 2005?
The short answer is that it was destroyed, in part byan association with gambling addiction, but mostlywhen it went generic. GSK reported Requip onlygenerated £58 million in sales worldwide lastquarter.
That raises a further question as to whether it is wise to launch Solzira againstcheap generics. As I have mentioned a couple of times recently, there's awell-established law of competition in the drug business: cheap generics win. Butwith this launch, GSK is joining Cephalon and Shire as companies that havedecided that this law somehow doesn't apply to them.
On its face, there is little evidence to suggest that GSK is right in coming to thisconclusion. Requip's life at GSK was short and unhappy. It generated $986 millionin sales from 2005 to 2007, according to this excellent MSNBC report. NielsenMonitor-Plus tells me that over the same period, GSK spent $248 millionadvertising Requip in TV and print ads. Put another way, 25 percent of Requip'srevenues were immediately burned by its adspend -- that's an astonishinglyinefficient marketing effort, and a stand-out example of why people believe thatdrug advertising makes medicine more expensive.
On the other hand, GSK may be eyeing a very different set of facts. Requip wasdogged by rumors that it causes a pathological gambling addiction among some ofits users. This is because it is a dopamine agonist, like its sister drug Mirapex,which produces a "high" that makes users think they are geniuses at roulette. Infact Requip's label has warnings about gambling on it.
The interesting thing, therefore, about the Solzira application is that it is not adopamine agonist. It's a gabapentin, and gabapentin isn't associated with the urgeto rent a limo and stay up all night in Atlantic City.
So maybe GSK thinks this new gabapentin, with its lower side effect profile, candominate lesser generics. Possibly. Until, of course, doctors wake up to the factthat there are already plenty of generic gabapentins on the market, such asNeurontin.
Which brings me back to my first point about the laws of competition in the drugbusiness ...© 2008 CBS Interactive Inc.. All Rights Reserved.
Comment / Shares / Tweets / Stumble / Email More +
Market Data
Enter Ticker Symbol or Company Name
NASDAQ: Oct 20, 2015
Symbol Last Change % Change
DOW 17,200.81 -29.73 -0.17%
NASDAQ 4,900.75 -4.73 -0.10%
S&P 500 2,031.31 +1,915.83 +1,659.01%
GlaxoSmithKline Bets Solzira Can Win Where Requip Failed... http://www.cbsnews.com/news/glaxosmithkline-bets-solzira-c...
1 di 4 20/10/15 15:47
Comment / Shares / Tweets / Stumble / Email More +
S H O W C O M M E N T S +
Featured in Moneywatch
10 cars you can keep for 10yearsThese SUVS, minivans and sedans arethe models that owners most oftenhang on to for a decade before sellingthem
10 best and worst deals atTargetTarget has some great steals, but not alldeals are really a deal -- here's what youshould and shouldn't buy
Popular
Powered by for youLearn more
Election 2016: How willDonald Trump pay for hiseconomic proposals?
Lamar Odom distraught overhis reputation, downfall
New images released ofFrance train hero stabbing
Iran sends fighters to Syria,using cover from Russia's aircampaign
Giant hole in the sun is thewidth of 50 Earths
Philip Chism, Massachusettsteen accused of killingteacher Colleen Ritzer, in
Treasury Secretary moves updebt limit deadline, pressuresCongress to act
Israel: Palestinian PresidentMahmoud Abbas incitingviolence over false death
Powered by for you
Recommended
Learn more
Legendary Nazi gold trainpossibly located
Donald Trump keeps upmomentum, targets BernieSanders
Photos of the week - Theweek in pictures - September26-October 2, 2015
Explosive CryptocurrencyReplacing the US Dollar?Wall Street Daily Sponsored
Watch CBSN Live
Watch CBS News anytime, anywherewith the new 24/7 digital news network.
Stream CBSN live or on demand forFREE on your TV, computer, tablet, or
smartphone.
Watch Now
Latest Features
6 tips for repaying your studentloan
A legal push to make VW buyback its diesels
Hershey's supersizes one ofits most popular treats
Amazon adding 100K jobs forholiday season
KFC parent Yum spinning offChina business
Market News
GlaxoSmithKline Bets Solzira Can Win Where Requip Failed... http://www.cbsnews.com/news/glaxosmithkline-bets-solzira-c...
2 di 4 20/10/15 15:47
Moneywatch Spotlight
9:42 AM Stocks edge lower in earlytrade; IBM weighs on Dowaverage
9:42 AM Balkan neighbors trade barbsas refugees flow into Slovenia
9:30 AM Iraq says forces recapturerefinery town from IS militants
9:19 AM EU, Turkey remain divided,despite shared migrantchallenge
9:19 AM Heartland BancCorp. posts 3Qprofit
9:17 AM Ex-Fukushima nuclear plantworker confirmed to havecancer
9:13 AM Apartments drive homeconstruction gains inSeptember
9:11 AM Cambridge posts 3Q profit9:09 AM NVR posts 3Q profit8:59 AM Settlement brewing in Beck's
beer case over Germanpackaging
MORE HEADLINES
The 13 most valuable startupsand spinoffs
10 best and worst deals atSam's Club211776 VIEWS
6 copycat houses that mimicfamous homes84117 VIEWS
10 cars you can keep for 10years16592 VIEWS
Holiday shopping countdown:5 ways to stay on track
Stock Watchlist
ADD
Oct 20, 2015
Enter Ticker Symbol or Company Name
Symbol Last Change % Change
AAPL 111.33 -0.40 -0.36%
GE 28.77 -0.22 -0.76%
KO 42.08 +0.09 +0.21%
WMT 58.88 +0.03 +0.05%
XOM 80.28 -0.71 -0.88%VIEW/EDIT YOUR FULL WATCHLIST
GlaxoSmithKline Bets Solzira Can Win Where Requip Failed... http://www.cbsnews.com/news/glaxosmithkline-bets-solzira-c...
3 di 4 20/10/15 15:47
Quotes delayed at least 15 minutes. Market data provided by Interactive Data. Terms & Conditions.Powered and implemented by Interactive Data Managed Solutions News provided by The Associated Press.Company fundamental data provided by Zacks.
New Android App
For your Android phone and tablet,download the FREE redesigned app,
featuring CBSN, live 24/7 news.
Download
CBSNews.com
Site MapHelpContact UsCBS BiosCareersInternshipsDevelopment Programs
CBS Interactive
Privacy PolicyAd ChoiceTerms of UseMobile User AgreementAbout CBSAdvertiseClosed Captioning
Follow Us
FacebookTwitterRSSEmail NewslettersYouTubeCBS Radio NewsCBS Local
Copyright © 2015 CBS Interactive Inc.All rights reserved.
Questo Natale, le personecercheranno un'attività come la
tua.
GlaxoSmithKline Bets Solzira Can Win Where Requip Failed... http://www.cbsnews.com/news/glaxosmithkline-bets-solzira-c...
4 di 4 20/10/15 15:47